Bayer: Group performance matches prior year despite declines at Crop Science

Group sales increase by 3.0 percent (Fx& portfolio adj.: plus 1.9 percent) to EUR 12,193 million / EBITDA before special items level with the prior year, at EUR 3,056 million (plus 0.1 percent) / Pharmaceuticals posts strong increase in earnings and margins / Brazil business weighs on Crop Science / Consumer Health encounters difficult market environment in the United States / Significant increase in sales and earnings at Covestro / Net income decreases by 11.3 percent to EUR 1,224 million / Core earnings per share EUR 1.81 (minus 12.6 percent) / Monsanto acquisition on track / Group outlook for 2017 adjusted
Source: Bayer Company News - Category: Pharmaceuticals Source Type: news